The latest clinical update includes dosing announcements for two trials, with the first patients now treated with Epicrispr Biotechnologies’ EPI-321...
Modalis Therapeutics has partnered with SOLVE FSHD to advance the development of an experimental epigenome-editing therapy for facioscapulohumeral...
Some of the best links we picked up around the internet
